Transendothelial migration (TEM) of in vitro generated dendritic cell vaccine in cancer immunotherapy
Archives of Pharmacal Research 2019³â 42±Ç 7È£ p.582 ~ p.590
(Ashraf Muhammad Umer) - Sungkyunkwan University Department of Biological Sciences
(Jeong Yi-Deul) - Sungkyunkwan University Department of Biological Sciences
(Roh Seung-Eon) - Johns Hopkins University School of Medicine Department of Neuroscience
¹è¿ë¼ö(Bae Yong-Soo) - Sungkyunkwan University Department of Biological Sciences
Abstract
Many efforts have been made to improve the efficacy of dendritic cell (DC) vaccines in DC-based cancer immunotherapy. One of these efforts is to deliver a DC vaccine more efficiently to the regional lymph nodes (rLNs) to induce stronger anti-tumor immunity. Together with chemotaxis, transendothelial migration (TEM) is believed to be a critical and indispensable step for DC vaccine migration to the rLNs after administration. However, the mechanism underlying the in vitro-generated DC TEM in DC-based cancer immunotherapy has been largely unknown. Currently, junctional adhesion molecules (JAMs) were found to play an important role in the TEM of in vitro generated DC vaccines. This paper reviews the TEM of DC vaccines and TEM-associated JAM molecules.
Å°¿öµå
chemotaxis, DC vaccine, cancer immunotherapy, JAMs, JAML, regional LNs
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
The various clinical studies exploring the DC vaccination in cancer patients have demonstrated that DC-based cancer vaccines are safe to use in clinical settings.